GI Insights

Gastric cancer risk in the United States varies substantially across populations, yet prevention remains largely based on symptoms. Join Dr. Peter Buch and Dr. Chul Hyun, Director of the Gastric Cancer Prevention and Screening Program at the Yale School of Medicine, as they explore how recognizing key risk factors may help us identify patients who warrant closer evaluation.

The American Society for Gastrointestinal Endoscopy (ASGE) recently released a new guideline on when to use endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) in managing early esophageal and gastric cancers. To learn more about when to use each approach, Dr. Peter Buch sits down with guideline co-author Dr. Vivek Kaul. Dr. Kaul is also the Segal-Watson Professor of Medicine at the University of Rochester Medical Center in New York.

While fecal immunochemical testing and multitarget stool DNA testing are commonly used to screen for colon cancer, screening rates remain low throughout the United States. With the introduction of blood-based testing modalities, noninvasive colon cancer screening is becoming more accessible than ever. Join host Dr. Peter Buch and Dr. Aasma Shaukat as they discuss the effectiveness of current and emerging methods as well as best practices for screening patients. Dr. Shaukat is the Robert M. and Mary H. Glickman Professor of Medicine at the NYU Grossman School of Medicine and the Co-Director of Translational Research, Education, and Careers and the Director of Outcomes Research in the Division of Gastroenterology and Hepatology at NYU.

Racial and ethnic bias prevent patients with colorectal cancer from receiving the highest quality of care. Dr. Neil Nandi is joined by Dr. Fola May, Assistant Professor of Medicine at UCLA, to discuss racial inequalities in access to care and screening for patients with colorectal cancer.

Screening for colorectal cancer is unique because there are several screening options available. So how can we balance the latest ACG Clinical Guidelines with patient preferences, cultural context, and insurance coverage to find the best screening option for our patients? Joining Dr. Peter Buch to discuss the updated recommendations is Dr. Aasma Shaukat, lead author of the 2021 ACG Clinical Guidelines for colorectal cancer screening.

From new guideline recommendations to a concert featuring the American College of Gastroenterology’s official band, a lot is being done to help raise awareness of the importance of screening for colorectal cancer. So how can you help increase screening rates in your own community? Get inspired with these creative initiatives shared by Dr. Neil Nandi and Dr. Samir Shah, President of the American College of Gastroenterology.

Adenoma detection rate (ADR) may help us better detect our patients’ risk of developing colorectal cancer. To explore what we need to know about this quality indicator, Dr. Peter Buch joins Dr. Aasma Shaukat from the New York University Grossman School of Medicine to talk about ADR.

Since the 1990s, clinicians have been seeing a significant increase in colorectal cancer among young patients, who are under the age of 50. A multidisciplinary approach is key as diagnostic and treatment considerations are specific to their age. Dive in with Dr. Peter Buch as he’s joined by Dr. David Liska, Section Chief of Oncology in the Department of Colorectal Surgery at the Cleveland Clinic.

While colorectal cancer is the second most common cause of cancer deaths, only a third of people between the ages of 45 and 75 are compliant with screening recommendations. However, cell-free DNA blood-based tests could become a new option for colorectal cancer screening. Dr. Peter Buch sits down with GI expert Dr. William Grady to discuss the efficacy of this new test and where it is in the FDA approval process.

Ulcerative colitis treatment continues to evolve with a growing range of targeted therapies, from S1P modulators to JAK inhibitors. Joining Dr. Peter Buch to discuss how clinicians can personalize care based on disease severity, safety profiles, and patient response is Dr. David Hudesman. He's a Professor in the Department of Medicine at NYU Grossman School of Medicine and the Director of NYU Langone’s Inflammatory Bowel Disease Center.